Test Price
2,800 AED✅ Home Collection Available
CHRNB2 Gene Epilepsy (Nocturnal Frontal Lobe Type 3) Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
- Diagnostic Sensitivity 99.9% – ISO‑certified NGS and RNA‑sequencing delineates pathogenic CHRNB2 variants with clinically actionable precision.
- VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection – Available daily from 8 AM to 11 PM across all UAE emirates.
- Post‑Test Clinical Tele‑Guidance – Direct, empathetic result interpretation by DHA‑licensed clinicians to bridge genetic data with personalised care.
- Insurance Direct Billing – Verify coverage via WhatsApp at +971 54 548 8731 (English support).
The CHRNB2 Gene Epilepsy (Nocturnal Frontal Lobe Type 3) Genetic Test employs advanced sequencing to confirm autosomal dominant nocturnal frontal lobe epilepsy with molecular certainty. DNA Labs UAE operates under DHA Facility License 1143 and adheres strictly to Federal Decree-Law No. 45 of 2021 on Personal Data Protection and Federal Law No. 2 of 2019 for health data security.
Service available in all UAE emirates – WhatsApp support in English.
Test Overview & Methodology
The CHRNB2 Gene Epilepsy (Nocturnal Frontal Lobe Type 3) Genetic Test uncovers pathogenic variants in the nicotinic cholinergic receptor subunit β2, confirming a molecular diagnosis of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). For UAE families, this test answers the clinical question behind clusters of nocturnal motor seizures, guiding precision therapy and family planning.
| Parameter | DNA Labs UAE Test | Closest Alternative |
|---|---|---|
| Methodology | NGS plus optional RNA‑Seq (full exon‑level resolution) | Single‑gene Sanger sequencing or panel without RNA support |
| Analytical Sensitivity | 99.9% (detects SNVs, indels, and deep intronic splicing variants) | ~95% (often misses regulatory variants) |
| Turnaround Time | 3–4 weeks (expedited clinical reporting) | 6–8 weeks typical |
| Sample Requirement | EDTA whole blood or FTA card (2–5 mL) | Blood or buccal swab only |
Physician Insight & Safety Protocols
“A positive CHRNB2 finding does not paint the full clinical picture; it must be interpreted alongside EEG, seizure semiology, and family history. While this test provides molecular certainty, the decision to adjust antiepileptic therapy should always be a joint physician‑patient decision. I personally ensure every patient receives a post‑test counselling session to translate genomics into a humane care path.”
– Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Medication Advisory
Do not discontinue or alter any prescribed medication (e.g., carbamazepine, oxcarbazepine) without consulting your treating physician. Abrupt changes can provoke seizure clusters or status epilepticus. This is a diagnostic tool, not a substitute for therapeutic management. Any medication adjustments must be supervised by the managing neurologist in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Safety Exclusion Criteria & Red Flags
- Sample rejection if haemolysed, clotted, or collected in incorrect tube (only EDTA whole blood or FTA card accepted).
- Do not use for children under 3 years without paediatric neurologist clearance; alternative buccal swab may be advised.
- Red Flag: If you experience a sudden increase in seizure frequency, prolonged seizure lasting more than 5 minutes, or loss of consciousness, proceed to the nearest emergency department immediately.
- Genetic testing in minors requires explicit guardian consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability; legal guardian must be present during home collection.
- Home collection eligibility: VIP Mobile Phlebotomy is available for eligible patients. Patients with active seizure disorders should arrange collection during supervised hours with a companion present.
Patient FAQ & Clinical Guidance
1. How will a positive CHRNB2 gene result change my epilepsy treatment?
A positive CHRNB2 result confirms autosomal dominant nocturnal frontal lobe epilepsy, enabling your neurologist to tailor sodium channel blocker therapy and provide definitive advice on inheritance risk for your children. The genetic finding is interpreted alongside EEG and clinical history for a comprehensive care plan.
2. Are NGS and RNA sequencing really necessary for just one gene?
NGS combined with RNA sequencing captures deep intronic and splicing variants that conventional Sanger sequencing misses, providing the highest diagnostic yield and reducing the need for repeated testing if a variant of uncertain significance appears. This dual approach maximises clinical utility for a single-gene epilepsy test.
3. What are the legal and privacy protections for my genetic data in the UAE?
Your DNA is processed solely within DHA‑licensed, ISO‑certified UAE facilities under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. No identifiable genetic information is shared without your explicit informed consent. All data is encrypted and stored within UAE borders.
4. How do I prepare for the blood collection appointment?
No special preparation is required. You may eat and drink normally. Please inform the phlebotomist of any medications you are taking, especially anticoagulants, as this may affect the collection process. The appointment takes approximately 15 minutes and can be scheduled from 8 AM to 11 PM daily.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under the regulatory oversight of the Dubai Health Authority (DHA) with Facility License Number 1143. All clinical genetic testing conforms to the highest standards of data protection and patient safety as mandated by UAE federal law.
- Data Protection: All genetic data is processed and stored in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health Data Security: Information and communication technology systems adhere to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Medical Liability: All clinical procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring patient consent and safety are prioritised throughout the testing cycle.
- ISO Certification: Our laboratory holds ISO 9001:2015 certification, guaranteeing quality management and continuous process improvement.
- Data Sovereignty: All genomic data remains within UAE territory and is never transferred abroad without explicit patient authorisation.
Clinical & Logistical Metadata
| Test Name | CHRNB2 Gene Epilepsy (Nocturnal Frontal Lobe Type 3) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks (expedited clinical reporting available) |
| Sample Type / Matrix | EDTA whole blood (2–5 mL) or FTA card |
| Methodology Used | Next‑Generation Sequencing (NGS) plus optional RNA‑Seq for comprehensive variant detection |
| ICD-10-CM Code | G40.0 (Localization-related [focal] [partial] idiopathic epilepsy and epileptic syndromes with seizures of localized onset) |
| LOINC Code | 94862-1 (CHRNB2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians